目的:探讨氨溴特罗联合布地奈德雾化吸入治疗婴幼儿喘息急性发作的临床疗效。方法:62例婴幼儿喘息急性发作患儿随机分为观察组30例和对照组32例。观察组采用氨溴特罗联合布地奈德雾化吸入治疗;对照组采用小儿肺热咳喘口服液联合布地奈德雾化吸入治疗。比较两组患儿体征症状的消失时间、临床疗效与药品不良反应。结果:观察组咳嗽、湿性啰音、气喘和肺部哮鸣音等症状消失时间均短于对照组(P<0.01)。观察组与对照组治疗后的总有效率分别为90.00%和62.50%,两组疗效分布差异有统计学意义(P<0.05);两组患儿均未发生药品不良反应。结论:氨溴特罗联合布地奈德雾化吸入治疗婴幼儿喘息急性发作的疗效良好,值得临床推广。 Objective: To investigate the clinical efficacy of ambroxol combined with budesonide inhalation in the treatment of infantile asthma attacks. Methods: Sixty-two infants with acute wheezing were randomly divided into observation group (n = 30) and control group (n = 32). In the observation group, inhalation of ambroxol and budesonide was used. In the control group, Hyperactivity and Hyperactivity in Children was used in combination with budesonide inhalation. The disappearance of signs and symptoms, clinical efficacy and adverse drug reactions in both groups were compared. Results: The disappearance time of cough, wet rales, wheezing and lung wheeze in observation group were shorter than those in control group (P <0.01). The total effective rates of the observation group and the control group after treatment were 90.00% and 62.50%, respectively. There was significant difference between the two groups in the distribution of therapeutic effects (P <0.05). No adverse drug reactions occurred in both groups. Conclusion: The efficacy of ambroxol combined with budesonide inhalation in the treatment of acute wheezing in infants and young children is good, which is worthy of clinical promotion.